Long-term efficacy and safety of tildrakizumab: 5-year results from the reSURFACE 1 and 2 Phase III trials in patients with moderate-to-severe plaque psoriasis
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.